Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial.

Julio RosenstockAhmed A KolkailahDarren K McGuireMark A EspelandMichaela MattheusEgon PfarrSøren S LundNikolaus Marxnull null

Published in: Diabetes, obesity & metabolism (2023)

Across the severity spectrum, linagliptin substantially reduced the hypoglycaemic burden versus glimepiride in patients with relatively early T2D at increased cardiovascular risk. This article is protected by copyright. All rights reserved.

Keyphrases

type diabetes
phase iii
study protocol
cardiovascular disease
clinical trial
phase ii